- Home
- BIIB vs NVR Comparison
BIIB vs NVR Comparison
Compare BIIB & NVR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BIIB
- NVR
- Stock Information
- Founded
- BIIB 1978
- NVR 1980
- Country
- BIIB United States
- NVR United States
- Employees
- BIIB 7605
- NVR 7000
- Industry
- BIIB Biotechnology: Pharmaceutical Preparations
- NVR Homebuilding
- Sector
- BIIB Health Care
- NVR Consumer Discretionary
- Exchange
- BIIB Nasdaq
- NVR Nasdaq
- Market Cap
- BIIB 18.8B
- NVR 21.1B
- IPO Year
- BIIB 1991
- NVR N/A
- Fundamental
- Price
- BIIB $131.20
- NVR $7,100.13
- Analyst Decision
- BIIB Buy
- NVR Buy
- Analyst Count
- BIIB 26
- NVR 4
- Target Price
- BIIB $194.95
- NVR $9,023.33
- AVG Volume (30 Days)
- BIIB 1.7M
- NVR 17.7K
- Earning Date
- BIIB 05-01-2025
- NVR 07-22-2025
- Dividend Yield
- BIIB N/A
- NVR N/A
- EPS Growth
- BIIB 26.39
- NVR 1.37
- EPS
- BIIB 10.12
- NVR 486.51
- Revenue
- BIIB $9,816,400,000.00
- NVR $10,742,590,000.00
- Revenue This Year
- BIIB N/A
- NVR N/A
- Revenue Next Year
- BIIB N/A
- NVR $0.13
- P/E Ratio
- BIIB $12.83
- NVR $14.63
- Revenue Growth
- BIIB 1.59
- NVR 9.09
- 52 Week Low
- BIIB $110.04
- NVR $6,562.85
- 52 Week High
- BIIB $238.00
- NVR $9,964.77
- Technical
- Relative Strength Index (RSI)
- BIIB 59.82
- NVR 47.80
- Support Level
- BIIB $123.97
- NVR $7,000.12
- Resistance Level
- BIIB $132.94
- NVR $7,249.99
- Average True Range (ATR)
- BIIB 3.49
- NVR 162.17
- MACD
- BIIB 1.04
- NVR -14.49
- Stochastic Oscillator
- BIIB 88.37
- NVR 17.76
About BIIB Biogen Inc.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.
About NVR NVR Inc.
NVR Inc is a United States-based homebuilding company. It builds single-family detached homes, townhomes, and condominium buildings under three brands, Ryan Homes, NVHomes, and Heartland Homes. The company through its subsidiary also operates a mortgage banking and title services business. The homebuilding segment includes four geographic areas of the Mid-Atlantic, North East, Mid-East, and South East.